FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972118861> ?p ?o ?g. }

• W1972118861 endingPage "387" @default.
• W1972118861 startingPage "377" @default.
• W1972118861 abstract "From September 1995 through April 2002, 286 patients with chronic hepatitis B were started on lamivudine at the Toranomon Hospital in Tokyo, Japan, and most of them continued with it. At present, 16 patients received lamivudine for 5 years, 7 of whom for 7 years or longer. YMDD mutants increased gradually and developed in 69% of them during the 7 years on lamivudine. Biochemical and virological responses were achieved in 9 of the 16 patients (56%) at 5 years, and in 4 of the 7 patients (57%) at 7 years. Histological assessments were performed at 3 years in the 16 patients and further at 4 and 7 years in the 7 patients. Necroinflammatory changes improved remarkably with a decrease in the total histological activity score from 11.3 +/- 3.0 to 4.1 +/- 1.7 (p < 0.0001) at 3 years in the 16 patients. Histological improvements continued in 4 of the 7 patients (57%) at 7 years on lamivudine, while the pathology was unchanged in 2 patients (29%) and aggravated in the remaining 1 patient (14%). Severe acute exacerbation of hepatitis developed in 1 patient, who received additional interferon-alpha therapy to cope with it. Based on my experience, the continuation of lamivudine in patients with chronic hepatitis B benefits approximately two thirds of them with persistent virological and biochemical responses accompanied by histological improvements. Breakthrough hepatitis induced by YMDD mutants along the way in a small number of patients needs to be diagnosed promptly by regular monitoring for transaminases and, if it develops, it can be treated with interferon or other antiviral agents." @default.
• W1972118861 created "2016-06-24" @default.
• W1972118861 creator A5044932403 @default.
• W1972118861 date "2003-01-01" @default.
• W1972118861 modified "2023-10-18" @default.
• W1972118861 title "Continued Lamivudine Therapy in Patients with Chronic Hepatitis B" @default.
• W1972118861 cites W2009283086 @default.
• W1972118861 cites W2009944703 @default.
• W1972118861 cites W2039229349 @default.
• W1972118861 cites W2039294886 @default.
• W1972118861 cites W2044553804 @default.
• W1972118861 cites W2053396830 @default.
• W1972118861 cites W2055270948 @default.
• W1972118861 cites W2077207642 @default.
• W1972118861 cites W2084713036 @default.
• W1972118861 cites W2090023899 @default.
• W1972118861 cites W2093604720 @default.
• W1972118861 cites W2112145547 @default.
• W1972118861 cites W2124012164 @default.
• W1972118861 cites W2134970942 @default.
• W1972118861 cites W2137544368 @default.
• W1972118861 cites W2146614792 @default.
• W1972118861 cites W2157989384 @default.
• W1972118861 cites W2161280033 @default.
• W1972118861 cites W2338794667 @default.
• W1972118861 cites W2393327590 @default.
• W1972118861 cites W2146003334 @default.
• W1972118861 doi "https://doi.org/10.1159/000074996" @default.
• W1972118861 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14688456" @default.
• W1972118861 hasPublicationYear "2003" @default.
• W1972118861 type Work @default.
• W1972118861 sameAs 1972118861 @default.
• W1972118861 citedByCount "10" @default.
• W1972118861 countsByYear W19721188612012 @default.
• W1972118861 crossrefType "journal-article" @default.
• W1972118861 hasAuthorship W1972118861A5044932403 @default.
• W1972118861 hasConcept C126322002 @default.
• W1972118861 hasConcept C203014093 @default.
• W1972118861 hasConcept C2522874641 @default.
• W1972118861 hasConcept C2776029263 @default.
• W1972118861 hasConcept C2776178377 @default.
• W1972118861 hasConcept C2777014857 @default.
• W1972118861 hasConcept C2777382497 @default.
• W1972118861 hasConcept C2777869810 @default.
• W1972118861 hasConcept C2909179924 @default.
• W1972118861 hasConcept C3020491458 @default.
• W1972118861 hasConcept C71924100 @default.
• W1972118861 hasConcept C90924648 @default.
• W1972118861 hasConceptScore W1972118861C126322002 @default.
• W1972118861 hasConceptScore W1972118861C203014093 @default.
• W1972118861 hasConceptScore W1972118861C2522874641 @default.
• W1972118861 hasConceptScore W1972118861C2776029263 @default.
• W1972118861 hasConceptScore W1972118861C2776178377 @default.
• W1972118861 hasConceptScore W1972118861C2777014857 @default.
• W1972118861 hasConceptScore W1972118861C2777382497 @default.
• W1972118861 hasConceptScore W1972118861C2777869810 @default.
• W1972118861 hasConceptScore W1972118861C2909179924 @default.
• W1972118861 hasConceptScore W1972118861C3020491458 @default.
• W1972118861 hasConceptScore W1972118861C71924100 @default.
• W1972118861 hasConceptScore W1972118861C90924648 @default.
• W1972118861 hasIssue "6" @default.
• W1972118861 hasLocation W19721188611 @default.
• W1972118861 hasLocation W19721188612 @default.
• W1972118861 hasOpenAccess W1972118861 @default.
• W1972118861 hasPrimaryLocation W19721188611 @default.
• W1972118861 hasRelatedWork W2002783910 @default.
• W1972118861 hasRelatedWork W2350834762 @default.
• W1972118861 hasRelatedWork W2357312806 @default.
• W1972118861 hasRelatedWork W2359884894 @default.
• W1972118861 hasRelatedWork W2375358607 @default.
• W1972118861 hasRelatedWork W2388430142 @default.
• W1972118861 hasRelatedWork W2413283326 @default.
• W1972118861 hasRelatedWork W2428865729 @default.
• W1972118861 hasRelatedWork W2461318346 @default.
• W1972118861 hasRelatedWork W2462074055 @default.
• W1972118861 hasVolume "46" @default.
• W1972118861 isParatext "false" @default.
• W1972118861 isRetracted "false" @default.
• W1972118861 magId "1972118861" @default.
• W1972118861 workType "article" @default.